Summary
Thirty-six (36) women with metastatic breast cancer refractory to conventional therapies were treated with cis-diamminedichloroplatinum II. Two dose schedules were used sequentially. The first 15 patients received platinum at a dose of 15 mg/m2 daily for 5 days at 28-day intervals. No response was noted in this group. Subsequently, 21 patients were treated with a dose of 100–120 mg/m2 at 28-day intervals, but with additional induced diuresis with saline, furosemide, and mannitol. Among 13 patients evaluable for response, 2 partial responses were observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hayes D, Cvitkovic E, Colby R, Scheiner E, Krakoff IH (1976) Amelioration of Renal Toxicity of Higher Dose Cis-platinum Diamminedichloride (CPDD) by Mannitol Induced Diuresis. Proc Am Assoc Cancer Res 17:169
Chary KK, Higby DJ, Henderson ES, Swinerton KD (1977) A Phase I Study of High-Dose cis-Diamminedichloroplatinum II with Forced Diuresis. Cancer Treatment Rep 61(3):367–370
Catane R, Douglass HO, Mittelman A (1977) A Phase II Study of High Dose cis-Diamminedichloroplatinum II (DDP) in Non-Testicular Tumors (Meeting Abstracts) Proc Am Assoc Cancer Res 18:115
Wiesenfeld M, Corder MP, Panther SK, Maguire LC (1978) Prevention of Cis-platinum II Diamminedichloride (CPDD) Nephrotoxicity (NT) with Outpatient Hydration and Mannitol (M) Diuresis (Meeting Abstract). Proc Am Assoc Cancer Res 19:111
Ostrow S, Egorin M, Hahn D, LeRoy A, Markus S, Aisner J, Chang P, Forman R, Bachur N, Wiernik PH (1979) High Dose Cis-Dichlorodiammine Platinum (C-DDP) Therapy: Pharmacokinetic Analysis and Toxicity using Furosemide (F) vs. Mannitol (M) Diuresis (Meeting Abstract). Proc Am Assoc Cancer Res 70:88
Hayat M, Baysass M, Brule G, Cappelaere P, Cattan A, Chauvergne J, Clavel B, Gouveia J, Guerrin J, Laufer J, Pommatau, E, Szpirglas H, Muggia F, Mathe G (1978) Cis-platinumdiammine-Dichloro (CDDP) in Chemotherapy of Cancers. Phase II Therapeutic Trials. Biocheme 60(9):935–940
Gale GR (1974) Platinum Compounds. Handbook of Experimental Pharmacology 38(2):829–840
Bull JM, Anderson T, Lippman ME, Cassidy JG, Gormley PE, Young RC (1974) A Phase II Trial of Cis-dichlorodiammine Platinum II (cis-DDP) in Breast and Ovarian Carcinomas (Meeting Abstract). Proc Am Assoc Cancer Res 19:87
Lawson DH, Moore MR, Smalley RV (1979) An Evaluation of Hexamethylmelamine, Cis-Diamminedichloroplatinum and Mitomycin-C in Advanced Breast Cancer (Meeting Abstract). Proc Am Assoc Cancer Res 20:369
Kolaric K, Roth A (1983) Phase II Clinical Trial of Cis-Dichlorodiammine Platinum (cis-DDP) for Antitumorigenic Activity in Previously Untreated Patients with Metatastic Breast Cancer. Cancer Chemother Pharmacol 11:108–112
Lee FH, Canetta R, Issell BF, Lenaz L (1983) New Platinum Complexes in Clinical Trials. Cancer Treatment Rev 10:39–51
Author information
Authors and Affiliations
Additional information
Supported in part by National Cancer Institute, Department of Health, Education and Welfare, Contract No 1-CM-67105
Rights and permissions
About this article
Cite this article
Martino, S., Samal, B.A., Singhakowinta, A. et al. A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer two dose schedules. J Cancer Res Clin Oncol 108, 354–356 (1984). https://doi.org/10.1007/BF00390472
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00390472